Related Experiment Video

Updated: May 8, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.1K

Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway

Man-Wei Hao1, Tian-Xing Zhang1, Dan Dong2

  • 1School of Pharmaceutical Sciences, Jilin University, Changchun, 130021, China.

Medical Oncology (Northwood, London, England)
|March 27, 2025
PubMed

Insights

Pancreatic cancer with KRAS G12D mutations is hard to treat. Combining MRTX1133 with SHP099 or Buparlisib synergistically inhibited cancer cell growth and boosted apoptosis, offering new hope.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Pancreatic cancer frequently harbors the KRAS G12D mutation, presenting a significant therapeutic challenge.
  • MRTX1133, a novel non-covalent inhibitor targeting KRAS G12D, demonstrates potential but is limited by resistance mechanisms.

Purpose of the Study:

  • To investigate the efficacy of combining MRTX1133 with SHP099 (a SHP2 inhibitor) or Buparlisib (a PI3K inhibitor) in preclinical models of KRAS G12D-mutated pancreatic cancer.
  • To evaluate the potential for synergistic effects and overcoming resistance to KRAS G12D inhibition.

Main Methods:

  • Cell viability assays were performed to assess the impact of single agents and combination therapies on pancreatic cancer cell lines.
  • Apoptosis assays were utilized to quantify the induction of programmed cell death in response to treatment.
  • Combination indices were calculated to determine synergistic, additive, or antagonistic effects.

Main Results:

  • The combination of MRTX1133 with either SHP099 or Buparlisib demonstrated synergistic inhibition of pancreatic cancer cell proliferation.
  • Combined treatment significantly enhanced apoptosis compared to single-agent therapies.
  • These findings suggest that dual inhibition strategies can overcome resistance pathways.

Conclusions:

  • Combination therapies involving MRTX1133 with SHP099 or Buparlisib show significant promise for treating KRAS G12D-mutated pancreatic cancer.
  • These novel combinations may offer improved clinical outcomes for patients with this challenging disease.
Keywords:
KRAS mutationBuparlisibDrug resistanceMRTX1133Pancreatic cancerSHP099

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

17.5K
Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models06:57

Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models

Published on: April 7, 2018

10.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K